NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK.
Drug Discov Today. 2010 Apr;15(7-8):287-99. doi: 10.1016/j.drudis.2010.02.007. Epub 2010 Mar 1.
Glaucoma is the most common age-related optic nerve disease and also the most common neuropathy, affecting approximately 60 million people worldwide in its most common forms. This figure is expected to rise to 80 million by 2020. Glaucoma is a neurodegenerative disease in which various triggers induce cascades of secondary events, which ultimately lead to apoptotic retinal ganglion cell (RGC) death. The main risk factor for glaucomatous nerve damage is raised pressure in the eye. Understanding the cascades mediating optic nerve damage enables the development of new, neuroprotective treatment strategies that might not only target the initial insult but also prevent or delay secondary neurodegeneration. Furthermore, neuroregeneration and repopulation of the visual pathway by stem or neural precursor cells is becoming possible. Increasing understanding of the pathways involved in directed axon growth and manipulation of stem and progenitor cells towards an RGC fate have facilitated first successes in animal models of glaucoma.
青光眼是最常见的年龄相关性视神经疾病,也是最常见的神经病变,在其最常见的形式中影响着全球约 6000 万人。到 2020 年,这一数字预计将上升到 8000 万。青光眼是一种神经退行性疾病,其中各种触发因素引发二级事件级联反应,最终导致视网膜神经节细胞 (RGC) 的凋亡性死亡。青光眼性神经损伤的主要危险因素是眼内压升高。了解介导视神经损伤的级联反应,能够开发新的神经保护治疗策略,这些策略不仅可以针对初始损伤,还可以预防或延迟继发性神经退行性变。此外,通过干细胞或神经前体细胞对视觉通路进行神经再生和再殖成为可能。对参与定向轴突生长的途径的理解不断增加,以及对干细胞和祖细胞向 RGC 命运的操纵,都促进了青光眼动物模型中的初步成功。